title: Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
abstract: Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor-positive breast cancer. Tamoxifen requires enzymatic activation by CYP 450 enzymes for the formation of clinically relevant metabolites, 4-OH-tamoxifen and endoxifen, which both have a greater affinity to the estrogen receptor and ability to inhibit cell proliferation when compared to the parent drug. CYP2D6 is the key enzyme in this biotransformation, and recent mechanistic, pharmacologic, and clinical pharmacogenetic evidence suggests that genetic variants and drug interaction by CYP2D6 inhibitors influence plasma concentrations of active tamoxifen metabolites and outcome of patients treated with adjuvant tamoxifen. Particularly, non-functional (poor metabolizer) and severely impaired (intermediate metabolizer) CYP2D6 variants are associated with higher recurrence rates. Accordingly, CYP2D6 genotyping prior to treatment for prediction of metabolizer status and outcome may open new avenues for the individualization of endocrine treatment choice and benefit. Moreover, strong CYP2D6 inhibitors such as the selective serotonin reuptake inhibitor paroxetine should be avoided as co-medication.
authors.affiliation: Dr. Margarete Fischer Bosch Institute of Clinical Pharmacology Stuttgart and University Tübingen, Germany.
authors.forename: Hiltrud
authors.initials: H
authors.lastname: Brauch
authors.forename: Werner
authors.initials: W
authors.lastname: Schroth
authors.forename: Michel
authors.initials: M
authors.lastname: Eichelbaum
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwab
authors.forename: Nadia
authors.initials: N
authors.lastname: Harbeck
references.citation: Pharmacogenetics. 1997 Jun;7(3):187-91
references.pmid: 9241658
references.citation: Breast Cancer Res Treat. 2008 Apr;108(3):421-6
references.pmid: 17541741
references.citation: Ann Oncol. 2007 Jul;18(7):1133-44
references.pmid: 17675394
references.citation: J Pharmacol Exp Ther. 1996 Jul;278(1):441-6
references.pmid: 8764380
references.citation: Pharmacogenet Genomics. 2006 Oct;16(10):755-66
references.pmid: 17001295
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3837-45
references.pmid: 17761971
references.citation: J Natl Cancer Inst. 2005 Jan 5;97(1):30-9
references.pmid: 15632378
references.citation: J Endocrinol. 1977 Nov;75(2):305-16
references.pmid: 591813
references.citation: J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
references.pmid: 14652237
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
references.pmid: 14618296
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
references.pmid: 15159443
references.citation: Lancet. 2005 Jul 30-Aug 5;366(9483):409-21
references.pmid: 16054942
references.citation: Clin Pharmacol Ther. 2006 Jul;80(1):61-74
references.pmid: 16815318
references.citation: Breast Cancer Res. 2007;9(1):R7
references.pmid: 17244352
references.citation: Breast Cancer Res. 2005;7(3):R284-90
references.pmid: 15987423
references.citation: Breast Cancer Res Treat. 2005 Jun;91(3):249-58
references.pmid: 15952058
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709
references.pmid: 16877740
references.citation: Breast Cancer Res Treat. 2004 May;85(2):151-9
references.pmid: 15111773
references.citation: Ann Oncol. 2007 May;18(5):859-67
references.pmid: 17301074
references.citation: Breast Cancer Res Treat. 1982;2(2):123-38
references.pmid: 6184101
references.citation: Cancer Res. 1989 Apr 15;49(8):2175-83
references.pmid: 2702659
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
references.pmid: 16288118
references.citation: J Pharmacol Exp Ther. 2006 Aug;318(2):503-12
references.pmid: 16690721
references.citation: J Natl Compr Canc Netw. 2006 Nov;4(10):971-9
references.pmid: 17112447
references.citation: Breast Cancer Res Treat. 2008 Jan;107(1):15-24
references.pmid: 18043895
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5187-93
references.pmid: 18024866
references.citation: Cancer Res. 1988 Apr 15;48(8):2304-8
references.pmid: 3349495
references.citation: Breast Cancer Res Treat. 2007 Jan;101(1):113-21
references.pmid: 17115111
references.citation: Lancet. 2006 Feb 18;367(9510):595-604
references.pmid: 16488803
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9312-8
references.pmid: 16361630